Bibliographie

Publié le 10/10/2014

Article réservé aux abonnés

1- Luzza F, Mancuso M, Imeneo M et al. Evidence favouring the gastro-oral route in the transmission of Helicobacter pylori infection in children. Eur J Gastroenterol Hepatol. 2000 Jun;12(6):623-7

2- Axon AT. Review article: is Helicobacter pylori transmitted by the gastro-oral route? Aliment Pharmacol Ther. 1995 Dec;9(6):585-8. Review

3- Haute autorité de Santé. Dépistage de l’infection à Helicobacter pylori. Pertinence et population concernées. Recommandations en santé publique. Avril 2010.

4- World Health Organization, International Agency for Research on Cancer. Schistosomes, liver flukes an Helicobacter pylori. In: IARC Monographs on the evaluation of carcinogenic risks to humans. Geneva: WHO; 1997.

5- Agence française de sécurité sanitaire des produits de santé. Prise en charge thérapeutique de l'éradication de Helicobacter pylori chez l'adulte et l'enfant. Saint-Denis: AFSSAPS; 2005.

6- Delchier JC. Manifestations digestives de l'infection à Helicobacter pylori chez l'adulte : de la gastrite au cancer gastrique. Presse Médicale 2008;37(3):519-24.

7- Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008;23(3):351-65

8- Institut national du cancer. La situation du cancer en France en 2009. Boulogne Billancourt: INCa; 2009

9- World Health Organization, International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Preambule. Geneva: WHO; 2006

10- Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120(12):977-81.

11- Delchier J-C. Helicobacter pylori : actualités thérapeutiques en 2012. Post'U, 2012, 1-6.

12- Haute Autorité de Santé. Guide ALD cancer de l’estomac. Septembre 2011.

13- Delchier JC. Lymphome gastrique du MALT : une maladie maligne potentiellement curable par l’éradication d’Helicbacter pylori. Gastroenterol Clin Biol 2003;27: 453-8

14- Lamarque D, Burucoa C, Courillon-Mallet A et al. Révision des recommandations françaises sur la prise en charge de l’infection par Helicobacter pylori. Hépato Gastro 2012 ; 19 : 475-502

15- Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007.

16- Chey WD, Wong BC. American College of Gastroenterology guideline on the management ofHelicobacter pylori infection. Am J Gastroenterol 2007;102(8):1808-25

17- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59(8):1143-53.

18- Dictionnaire Vidal® 2014

19- Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007 Apr 17;146(8):556-63

20- Malfertheiner P, Bazzoli F, Delchier JC, et al; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13.

21- Take S, Mizuno M, Ishiki K et al. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. J Gastroenterol. 2012 Jun;47(6):641-6

22- Dinis-Ribeiro M, Areia M, de Vries AC et al. European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012 Jan;44(1):74-94

23- Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009 Jul 21;151(2):121-8. Erratum in: Ann Intern Med. 2009 Oct 6;151(7):516

24- Ribrag V. Lymphome MALT. (page consultée le 16/9/2014). Orphanet

25- Haute Autorité de Santé. Les inhibiteurs de la pompe à protons chez l’adulte. Bon usage du médicament. Décembre 2009.

26- Ford AC, Delaney BC, Forman D, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004 ; 99 : 1833-55

27- Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non ulcer dyspepsia. Cochrane Database Syst Rev 2003 ; 1 : CD002096

28- Leung WK, Ng EK, Chan WY, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005 ; 14 : 2982-6.

29- Giuliani A, Galati G, Demoro M, et al. Screening of Helicobacter pylori infection after gastrectomy for cancer or peptic ulcer: results of a cohort study. Arch Surg 2010 ; 145 : 962-7

30- Yang HB, Sheu BS, Wang ST, et al. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009 ; 104 : 1642-9

31- Pilotto A, Franceschi M, Leandro G et al. Noninvasive diagnosis of Helicobacter pylori infection in older subjects: comparison of the 13C-urea breath test with serology. J Gerontol A Biol Sci Med Sci 2000 ; 55 : M163-7

32- Lamarque D. Traitement de l’infection par Helicobacter pylori. Rev Prat 2014 Fev ; 64 : 207-210

33- Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004 (99) : 823-239.

34- Peitz U, Leodolter A, Wex T et al. Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding. Z Gastroenterol 2004 (42) : 141-146.